Published in Anesthesiology on September 01, 1970
Lignocaine disposition in blood in epilepsy. Br J Clin Pharmacol (1981) 1.35
Effects of beta-adrenoceptor antagonists on the pharmacokinetics of lignocaine. Br J Clin Pharmacol (1984) 1.03
Bupivacaine and lignocaine for ophthalmic surgery. Br J Ophthalmol (1987) 0.99
Comparative circulating serum levels of mepivacaine with levo-nordefrin and lidocaine with epinephrien. Anesth Prog (1980) 0.88
Long-acting local anesthetics in dentistry. Anesth Prog (1992) 0.87
Circulating serum levels of mepivacaine after dental injection. Anesth Prog (1979) 0.82
Age does not influence the serum protein binding of bupivacaine. Br J Clin Pharmacol (1991) 0.78
alpha 1-Acid glycoprotein and plasma lidocaine binding. Clin Pharmacokinet (1984) 0.75
A randomised controlled trial to compare local with general anaesthesia for short-stay inguinal hernia repair. Ann R Coll Surg Engl (1983) 0.75
Local anesthetics and regional anesthesia. Calif Med (1972) 0.75
Effect of dehydration and hyperosmolal hydration on lignocaine and metabolites disposition in conscious rabbits. Br J Pharmacol (1994) 0.75
Treatment of local anesthetic toxicity. Anesth Prog (1999) 0.75
Comparison of lidocaine with and without bupivacaine for local dental anesthesia. Anesth Prog (1997) 0.75
Intra-articular (IA) ropivacaine microparticle suspensions reduce pain, inflammation, cytokine, and substance p levels significantly more than oral or IA celecoxib in a rat model of arthritis. Inflammation (2015) 0.75
Mammalian and bacterial sugar transport proteins are homologous. Nature (1987) 4.46
Inhibition of antipyrine metabolism by beta-adrenoceptor antagonists. Br J Clin Pharmacol (1981) 3.07
Oxidation phenotype--a major determinant of metoprolol metabolism and response. N Engl J Med (1982) 2.72
"No paresthesias-no anesthesia," the nerve stimulator or neither? Reg Anesth (1997) 2.52
Determination of debrisoquine and its 4-hydroxy metabolite in biological fluids by gas chromatography with flame-ionization and nitrogen-selective detection. J Chromatogr (1977) 2.43
Amiodarone pharmacokinetics. Am Heart J (1983) 2.42
Metformin kinetics in healthy subjects and in patients with diabetes mellitus. Br J Clin Pharmacol (1981) 2.38
Peripheral nerve damage and regional anaesthesia. Br J Anaesth (1994) 2.16
Inhibition of oxidative drug metabolism by beta-adrenoceptor antagonists in related to their lipid solubility. Br J Clin Pharmacol (1981) 2.08
Influence of first-pass effect on availability of drugs on oral administration. J Pharm Sci (1971) 2.08
Rotating the epidural needle: a caution--where is the clinical proof? Anesth Analg (1994) 1.95
The tissue distribution, metabolism and excretion of lidocaine in rats, guinea pigs, dogs and man. J Pharmacol Exp Ther (1972) 1.88
Celiac plexus block: a roentgenographic, anatomic study of technique and spread of solution in patients and corpses. Anesth Analg (1981) 1.75
The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol (1992) 1.71
Polymorphic hydroxylation of debrisoquine. Lancet (1977) 1.69
Plasma concentrations of local anaesthetics after interscalene brachial plexus block. Br J Anaesth (1977) 1.66
Metoprolol metabolism and debrisoquine oxidation polymorphism--population and family studies. Br J Clin Pharmacol (1985) 1.64
Lack of effect of atenolol on antipyrine clearance. Br J Clin Pharmacol (1982) 1.51
Computed tomography eliminates paraplegia and/or death from neurolytic celiac plexus block. Reg Anesth Pain Med (1999) 1.49
Sunlight--can it prevent as well as cause cancer? Cancer Res (1995) 1.48
Clinical pharmacokinetics of local anaesthetics. Clin Pharmacokinet (1979) 1.47
Bupivacaine: a review of 11,080 cases. Anesth Analg (1978) 1.46
Pharmacokinetics of lidocaine in man. Clin Pharmacol Ther (1971) 1.45
Caffeine urinary metabolite ratios as markers of enzyme activity: a theoretical assessment. Pharmacogenetics (1996) 1.41
Gerontokinetics--a reappraisal. Br J Clin Pharmacol (1992) 1.41
Preemptive analgesia--is it clinically relevant? Anesth Analg (1994) 1.40
Meperidine kinetics in man. Intravenous injection in surgical patients and volunteers. Clin Pharmacol Ther (1975) 1.39
Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes. Biochem Pharmacol (1997) 1.37
Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes. J Pharmacol Exp Ther (1988) 1.37
Measurement of the renal clearance of drugs. Br J Clin Pharmacol (1981) 1.35
Abdominal pain and alcohol celiac plexus nerve block. Anesth Analg (1977) 1.32
Metoprolol and debrisoquin metabolism in Nigerians: lack of evidence for polymorphic oxidation. Clin Pharmacol Ther (1986) 1.32
Polymorphic drug oxidation: pharmacokinetic basis and comparison of experimental indices. Br J Clin Pharmacol (1986) 1.29
Lignocaine and indocyanine green kinetics in patients following myocardial infarction. Br J Clin Pharmacol (1980) 1.28
Cloning and molecular characterization of plasmid-encoded antigens of Borrelia burgdorferi. Infect Immun (1999) 1.26
Why hypertensive patients vary in their response to oral debrisoquine. Br Med J (1977) 1.25
Prediction of in vivo drug clearance from in vitro data. I: impact of inter-individual variability. Xenobiotica (2006) 1.24
Oxidation of methamphetamine and methylenedioxymethamphetamine by CYP2D6. Drug Metab Dispos (1997) 1.23
Differential stereoselective metabolism of metoprolol in extensive and poor debrisoquin metabolizers. Clin Pharmacol Ther (1983) 1.22
Population pharmacokinetics of methadone in opiate users: characterization of time-dependent changes. Br J Clin Pharmacol (1999) 1.21
Classical versus low-segment transverse incision for preterm caesarean section: maternal complications and outcome of subsequent pregnancies. Br J Obstet Gynaecol (1988) 1.20
The disposition of debrisoquine in hypertensive patients. Br J Clin Pharmacol (1978) 1.16
Enterocytic CYP3A4 in a paediatric population: developmental changes and the effect of coeliac disease and cystic fibrosis. Br J Clin Pharmacol (2001) 1.15
Tourniquet pain: a volunteer study. Anesth Analg (1986) 1.11
Inter-individual variability in levels of human microsomal protein and hepatocellularity per gram of liver. Br J Clin Pharmacol (2003) 1.11
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is N-demethylated by cytochromes P450 2D6, 1A2 and 3A4--implications for susceptibility to Parkinson's disease. J Pharmacol Exp Ther (1996) 1.11
Lactic acidosis during metformin treatment in an elderly diabetic patient with impaired renal function. Acta Med Scand (1981) 1.11
Circadian hydrocortisone infusions in patients with adrenal insufficiency and congenital adrenal hyperplasia. Clin Endocrinol (Oxf) (2006) 1.10
Pharmacokinetic aspects of intravenous regional anesthesia. Anesthesiology (1971) 1.10
Mechanism-based inactivation of CYP2D6 by methylenedioxymethamphetamine. Drug Metab Dispos (2004) 1.10
Spinal (subarachnoid) block. A review of 11,574 cases. JAMA (1966) 1.09
Intercostal nerve block for postoperative somatic pain following surgery of thorax and upper abdomen. Br J Anaesth (1975) 1.09
Altered plasma drug binding in cancer: role of alpha 1-acid glycoprotein and albumin. Clin Pharmacol Ther (1982) 1.08
The position of plastic tubing in continuous-block techniques: an x-ray study of 552 patients. Anesthesiology (1968) 1.08
Routine detection and identification in urine of stimulants and other drugs, some of which may be used to modify performance in sport. J Pharm Pharmacol (1967) 1.08
Polymorphic metabolism of beta-adrenoceptor antagonists. Br J Clin Pharmacol (1984) 1.08
Meperidine and other basic drugs: general method for their determination in plasma. J Pharm Sci (1974) 1.08
Timolol and atenolol: relationships between oxidation phenotype, pharmacokinetics and pharmacodynamics. Br J Clin Pharmacol (1985) 1.07
A simplified maneuver for transarterial approach to axillary block for use by a single anesthesiologist--needs more explanation! Reg Anesth (1997) 1.07
Haemodynamic effects of prenalterol in patients with coronary heart disease. Br Heart J (1980) 1.07
Systemic absorption of mepivacaine in commonly used regional block procedures. Anesthesiology (1972) 1.06
Predicting drug clearance from recombinantly expressed CYPs: intersystem extrapolation factors. Xenobiotica (2004) 1.05
Evidence that aspartic acid 301 is a critical substrate-contact residue in the active site of cytochrome P450 2D6. J Biol Chem (1995) 1.05
Pharmacokinetics of local anaesthetics. Br J Anaesth (1986) 1.04
Pethidine revisited: plasma concentrations and effects after intramuscular injection. Br J Anaesth (1975) 1.04
Journal impact factors: a 'bioequivalence' issue? Br J Clin Pharmacol (2001) 1.04
Modified-release hydrocortisone for circadian therapy: a proof-of-principle study in dexamethasone-suppressed normal volunteers. Clin Endocrinol (Oxf) (2007) 1.04
Effects of beta-adrenoceptor antagonists on the pharmacokinetics of lignocaine. Br J Clin Pharmacol (1984) 1.03
Prediction of systemic availability from plasma-level data after oral drug administration. J Pharm Pharmacol (1973) 1.02
Amiodarone pharmacokinetics. Br J Clin Pract Suppl (1986) 1.02
Subdural intracranial air: an unusual cause of headache after epidural steroid injection. Anesthesiology (1991) 1.01
The antitussive effect of dextromethorphan in relation to CYP2D6 activity. Br J Clin Pharmacol (1999) 1.01
The polymorphic oxidation of beta-adrenoceptor antagonists. Clinical pharmacokinetic considerations. Clin Pharmacokinet (1986) 1.00
Hormonal changes during puberty: V. Transient pubertal gynecomastia: abnormal androgen-estrogen ratios. J Clin Endocrinol Metab (1984) 1.00
The pharmacokinetics of methadone in healthy subjects and opiate users. Br J Clin Pharmacol (1997) 1.00
The components of an effective test dose prior to epidural block. Anesthesiology (1981) 1.00
Oral absorption and disposition kinetics of lidocaine hydrochloride in dogs. J Pharmacol Exp Ther (1970) 1.00
Testing for bimodality in frequency distributions of data suggesting polymorphisms of drug metabolism--hypothesis testing. Br J Clin Pharmacol (1989) 0.99
Acebutolol in hypertension: relationships between drug concentration and effects. Eur J Clin Pharmacol (1978) 0.99
Testing for bimodality in frequency distributions of data suggesting polymorphisms of drug metabolism--histograms and probit plots. Br J Clin Pharmacol (1989) 0.99
Autogeneic bone marrow and porous biphasic calcium phosphate ceramic for segmental bone defects in the canine ulna. Clin Orthop Relat Res (1991) 0.98
Determination of metformin in biological samples. Br J Clin Pharmacol (1978) 0.98
In-vivo indices of enzyme activity: the effect of renal impairment on the assessment of CYP2D6 activity. Pharmacogenetics (1999) 0.96
New antiarrhythmic agents. 1. Primary alpha-amino anilides. J Med Chem (1979) 0.96
Backtracking booze with Bayes--the retrospective interpretation of blood alcohol data. Br J Clin Pharmacol (1991) 0.95
Towards a quantitative framework for the prediction of DDIs arising from cytochrome P450 induction. Curr Drug Metab (2009) 0.95
Disposition kinetics of ropivacaine in humans. Anesth Analg (1989) 0.95
The relationship between debrisoquine oxidation phenotype and the pharmacokinetics and pharmacodynamics of propranolol. Br J Clin Pharmacol (1984) 0.94
Inhibition of metoprolol metabolism by chloroquine and other antimalarial drugs. J Pharm Pharmacol (1990) 0.94
The use of tolbutamide-induced hypoglycemia to examine the intraislet role of insulin in mediating glucagon release in normal humans. J Clin Endocrinol Metab (1997) 0.93
Bupivacaine hydrochloride: laboratory and clinical studies. Anesthesiology (1970) 0.93
Relevance of induction of human drug-metabolizing enzymes: pharmacological and toxicological implications. Br J Clin Pharmacol (1996) 0.92
Prediction of metabolic drug clearance in humans: in vitro-in vivo extrapolation vs allometric scaling. Xenobiotica (2006) 0.92
Sequence conservation in the 3'-untranslated regions of neurone-specific enolase, lymphokine and protooncogene mRNAs. FEBS Lett (1987) 0.92
Cardiovascular effects of prenalterol (H133/22) in normal man. Br J Clin Pharmacol (1979) 0.91